Unravelling the molecular interplay: SUMOylation, PML nuclear bodies and vascular cell activity in health and disease.

Autor: Berkholz J; Institute of Physiology, Charité - Universitätsmedizin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany. Electronic address: janine.berkholz@charite.de., Karle W; Institute of Physiology, Charité - Universitätsmedizin, Berlin, Germany.
Jazyk: angličtina
Zdroj: Cellular signalling [Cell Signal] 2024 Jul; Vol. 119, pp. 111156. Date of Electronic Publication: 2024 Apr 02.
DOI: 10.1016/j.cellsig.2024.111156
Abstrakt: In the seemingly well-researched field of vascular research, there are still many underestimated factors and molecular mechanisms. In recent years, SUMOylation has become increasingly important. SUMOylation is a post-translational modification in which small ubiquitin-related modifiers (SUMO) are covalently attached to target proteins. Sites where these SUMO modification processes take place in the cell nucleus are PML nuclear bodies (PML-NBs) - multiprotein complexes with their essential main component and organizer, the PML protein. PML and SUMO, either alone or as partners, influence a variety of cellular processes, including regulation of transcription, senescence, DNA damage response and defence against microorganisms, and are involved in innate immunity and inflammatory responses. They also play an important role in maintaining homeostasis in the vascular system and in pathological processes leading to the development and progression of cardiovascular diseases. This review summarizes information about the function of SUMO(ylation) and PML(-NBs) in the human vasculature from angiogenesis to disease and highlights their clinical potential as drug targets.
Competing Interests: Declaration of competing interest The authors declare no conflict of interest.
(Copyright © 2023. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: